Symbols / ANRO Stock $24.40 +0.54% Alto Neuroscience, Inc.

Healthcare • Biotechnology • United States • NYQ
ANRO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Amit Etkin M.D., Ph.D.
Exch · Country NYQ · United States
Market Cap 855.29M
Enterprise Value 622.79M
Income -63.24M
Sales —
FCF (ttm) -33.95M
Book/sh 4.74
Cash/sh 5.53
Employees 68
Insider 10d —
IPO Feb 02, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -10.73
PEG —
P/S —
P/B 5.15
P/C —
EV/EBITDA -9.48
EV/Sales —
Quick Ratio 15.58
Current Ratio 15.69
Debt/Eq 15.85
LT Debt/Eq —
EPS (ttm) -2.19
EPS next Y -2.27
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-03-16
ROA -22.90%
ROE -41.80%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 35.05M
Shs Float 21.80M
Insider Own 6.25%
Instit Own 77.17%
Short Float 7.48%
Short Ratio 5.66
Short Interest 2.19M
52W High 28.44
vs 52W High -14.21%
52W Low 2.12
vs 52W Low 1,050.94%
Beta 2.06
Impl. Vol. 1.15%
Rel Volume 0.38
Avg Volume 296.51K
Volume 113.52K
Target (mean) $35.27
Tgt Median $35.00
Tgt Low $21.00
Tgt High $50.00
# Analysts 9
Recom Strong_buy
Prev Close $24.27
Price $24.40
Change 0.54%
About

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$35.27
Mean price target
2. Current target
$24.40
Latest analyst target
3. DCF / Fair value
$-17.43
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.40
Low
$21.00
High
$50.00
Mean
$35.27

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-22 main Chardan Capital Buy → Buy $30
2026-04-02 main Baird Outperform → Outperform $38
2026-04-02 reit HC Wainwright & Co. Buy → Buy $50
2026-04-02 main Jones Trading Buy → Buy $44
2026-04-02 main Wedbush Neutral → Neutral $21
2026-04-02 main Chardan Capital Buy → Buy $30
2026-03-18 main Baird Outperform → Outperform $41
2026-03-17 main Chardan Capital Buy → Buy $30
2026-03-17 main Wedbush Neutral → Neutral $22
2026-02-17 main BTIG Buy → Buy $28
2026-01-05 main Chardan Capital Buy → Buy $30
2025-11-17 init BTIG — → Buy $27
2025-11-13 main Baird Outperform → Outperform $22
2025-11-12 main Jefferies Buy → Buy $25
2025-10-24 main HC Wainwright & Co. Buy → Buy $50
2025-10-20 main Baird Outperform → Outperform $16
2025-09-29 init Chardan Capital — → Buy $15
2025-08-18 reit HC Wainwright & Co. Buy → Buy $10
2025-06-26 reit HC Wainwright & Co. Buy → Buy $10
2025-05-15 reit Wedbush Neutral → Neutral $4
News
RSS: Latest ANRO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-07-10 SAVITZ ADAM Officer — 15,000 $12.53 $190,833
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
66.36
-3.27%
68.61
+81.46%
37.81
+37.71%
27.45
Research And Development
45.62
-2.93%
47.00
+55.15%
30.29
+27.87%
23.69
Selling General And Administration
20.75
-4.02%
21.61
+187.50%
7.52
+36.59%
5.50
General And Administrative Expense
20.75
-4.02%
21.61
+187.50%
7.52
+36.59%
5.50
Other Gand A
20.75
-4.02%
21.61
+187.50%
7.52
+36.59%
5.50
Other Operating Expenses
—
—
—
-1.74
Total Expenses
66.36
-3.27%
68.61
+81.46%
37.81
+37.71%
27.45
Operating Income
-66.36
+3.27%
-68.61
-81.46%
-37.81
-37.71%
-27.45
Total Operating Income As Reported
66.36
-3.27%
68.61
+281.46%
-37.81
-29.52%
-29.19
EBITDA
-60.11
-0.93%
-59.55
-72.31%
-34.56
-26.29%
-27.37
Normalized EBITDA
-59.43
+0.21%
-59.55
-72.31%
-34.56
-28.01%
-27.00
Reconciled Depreciation
0.66
+31.67%
0.50
+34.58%
0.37
+9.06%
0.34
EBIT
-60.77
-1.19%
-60.06
-71.91%
-34.94
-26.07%
-27.71
Total Unusual Items
-0.68
0.00
-100.00%
0.53
+242.28%
-0.37
Total Unusual Items Excluding Goodwill
-0.68
0.00
-100.00%
0.53
+242.28%
-0.37
Special Income Charges
-0.68
0.00
—
—
Other Special Charges
0.68
—
—
—
Net Income
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Pretax Income
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Net Non Operating Interest Income Expense
4.13
-44.70%
7.48
+663.64%
0.98
+758.77%
0.11
Interest Expense Non Operating
2.47
+79.56%
1.38
+0.36%
1.37
0.00
Net Interest Income
4.13
-44.70%
7.48
+663.64%
0.98
+758.77%
0.11
Interest Expense
2.47
+79.56%
1.38
+0.36%
1.37
0.00
Interest Income Non Operating
6.60
-25.40%
8.85
+276.80%
2.35
+1960.53%
0.11
Interest Income
6.60
-25.40%
8.85
+276.80%
2.35
+1960.53%
0.11
Other Income Expense
-1.01
-239.39%
-0.30
-156.57%
0.53
+242.28%
-0.37
Other Non Operating Income Expenses
-0.33
-10.10%
-0.30
-156.57%
0.53
—
Gain On Sale Of Security
—
—
0.53
+242.28%
-0.37
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Net Income From Continuing Operation Net Minority Interest
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Net Income From Continuing And Discontinued Operation
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Net Income Continuous Operations
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Normalized Income
-62.56
-1.83%
-61.43
-69.21%
-36.30
-32.79%
-27.34
Net Income Common Stockholders
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Diluted EPS
—
-2.50
-76.11%
-1.42
+33.50%
-2.13
Basic EPS
—
-2.50
-76.11%
-1.42
+33.50%
-2.13
Basic Average Shares
—
24.60
-3.80%
25.57
+97.03%
12.98
Diluted Average Shares
—
24.60
-3.80%
25.57
+97.03%
12.98
Diluted NI Availto Com Stockholders
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
184.69
+4.03%
177.54
+104.95%
86.63
+70.35%
50.85
Current Assets
177.72
+4.95%
169.34
+98.31%
85.39
+73.49%
49.22
Cash Cash Equivalents And Short Term Investments
176.48
+4.91%
168.23
+103.80%
82.55
+70.75%
48.34
Cash And Cash Equivalents
176.48
+4.91%
168.23
+103.80%
82.55
+70.75%
48.34
Receivables
—
—
0.01
-97.60%
0.33
Accounts Receivable
—
—
—
0.33
Other Receivables
—
—
0.01
-97.60%
0.33
Prepaid Assets
1.23
+11.37%
1.11
+112.26%
0.52
+58.18%
0.33
Current Deferred Assets
—
0.00
-100.00%
2.21
0.00
Other Current Assets
—
0.03
-73.21%
0.11
-47.42%
0.21
Total Non Current Assets
6.97
-15.04%
8.21
+563.30%
1.24
-24.30%
1.63
Net PPE
6.13
-20.36%
7.70
+596.29%
1.11
-5.71%
1.17
Gross PPE
7.66
-12.02%
8.71
+386.31%
1.79
+2.17%
1.75
Accumulated Depreciation
-1.53
-51.99%
-1.00
-46.78%
-0.68
-18.13%
-0.58
Properties
0.00
0.00
0.00
—
Buildings And Improvements
—
5.04
0.00
—
Machinery Furniture Equipment
1.03
-8.14%
1.12
+89.81%
0.59
-5.00%
0.62
Other Properties
6.39
-13.01%
7.34
+511.24%
1.20
+6.10%
1.13
Leases
0.25
+0.00%
0.25
0.00
—
Other Non Current Assets
0.84
+66.27%
0.50
+284.73%
0.13
-71.58%
0.46
Total Liabilities Net Minority Interest
33.55
+28.62%
26.08
-83.52%
158.30
+77.35%
89.26
Current Liabilities
11.32
+13.16%
10.01
+78.40%
5.61
+0.90%
5.56
Payables And Accrued Expenses
9.59
+4.94%
9.14
+66.60%
5.49
+3.94%
5.28
Payables
1.88
+18.94%
1.58
+47.02%
1.07
-33.13%
1.61
Accounts Payable
1.88
+18.94%
1.58
+47.02%
1.07
-33.13%
1.61
Current Accrued Expenses
7.71
+2.01%
7.56
+71.37%
4.41
+20.16%
3.67
Current Debt And Capital Lease Obligation
1.74
+99.54%
0.87
+596.00%
0.12
-55.83%
0.28
Current Debt
0.58
—
—
—
Other Current Borrowings
0.58
—
—
—
Current Capital Lease Obligation
1.15
+32.30%
0.87
+596.00%
0.12
-55.83%
0.28
Other Current Liabilities
—
—
0.52
—
Total Non Current Liabilities Net Minority Interest
22.22
+38.25%
16.07
-89.47%
152.69
+82.43%
83.70
Long Term Debt And Capital Lease Obligation
22.22
+38.25%
16.07
+63.01%
9.86
+4.18%
9.46
Long Term Debt
18.40
+59.19%
11.56
+17.21%
9.86
+4.18%
9.46
Long Term Capital Lease Obligation
3.82
-15.35%
4.52
0.00
—
Other Non Current Liabilities
—
—
—
0.12
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
141.48
+95.86%
72.23
Stockholders Equity
151.14
-0.21%
151.46
+311.32%
-71.67
-86.62%
-38.41
Common Stock Equity
151.14
-0.21%
151.46
+311.32%
-71.67
-86.62%
-38.41
Capital Stock
0.00
+0.00%
0.00
0.00
0.00
Common Stock
0.00
+0.00%
0.00
0.00
0.00
Share Issued
31.92
+18.29%
26.99
+5.52%
25.57
+0.00%
25.57
Ordinary Shares Number
31.92
+18.29%
26.99
+5.52%
25.57
+0.00%
25.57
Additional Paid In Capital
352.75
+21.66%
289.95
+5297.51%
5.37
+133.57%
2.30
Retained Earnings
-201.63
-45.69%
-138.40
-79.82%
-76.97
-89.29%
-40.66
Gains Losses Not Affecting Retained Earnings
0.02
+121.78%
-0.10
-27.85%
-0.08
-71.74%
-0.05
Other Equity Adjustments
0.02
+121.78%
-0.10
-27.85%
-0.08
-71.74%
-0.05
Total Equity Gross Minority Interest
151.14
-0.21%
151.46
+311.32%
-71.67
-86.62%
-38.41
Total Capitalization
169.54
+4.00%
163.02
+363.74%
-61.81
-113.58%
-28.94
Working Capital
166.39
+4.43%
159.33
+99.71%
79.78
+82.73%
43.66
Invested Capital
170.13
+4.36%
163.02
+363.74%
-61.81
-113.58%
-28.94
Total Debt
23.96
+41.40%
16.94
+69.68%
9.99
+2.44%
9.75
Capital Lease Obligations
4.97
-7.65%
5.39
+4208.80%
0.12
-55.83%
0.28
Net Tangible Assets
151.14
-0.21%
151.46
+311.32%
-71.67
-86.62%
-38.41
Tangible Book Value
151.14
-0.21%
151.46
+311.32%
-71.67
-86.62%
-38.41
Derivative Product Liabilities
—
0.00
-100.00%
1.35
-27.97%
1.88
Interest Payable
0.12
+51.28%
0.08
-7.14%
0.08
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-51.77
-9.16%
-47.42
-41.78%
-33.45
-64.01%
-20.39
Cash Flow From Continuing Operating Activities
-51.77
-9.16%
-47.42
-41.78%
-33.45
-64.01%
-20.39
Net Income From Continuing Operations
-63.24
-2.94%
-61.43
-69.21%
-36.30
-31.02%
-27.71
Depreciation Amortization Depletion
0.66
+31.67%
0.50
+34.58%
0.37
+9.06%
0.34
Depreciation
0.66
+31.67%
0.50
—
—
Depreciation And Amortization
0.66
+31.67%
0.50
+34.58%
0.37
+9.06%
0.34
Other Non Cash Items
1.83
+3.86%
1.76
+1066.89%
0.15
-42.59%
0.26
Stock Based Compensation
8.11
+6.25%
7.63
+163.96%
2.89
+63.98%
1.76
Operating Gains Losses
0.84
+1509.62%
0.05
-62.86%
0.14
-62.06%
0.37
Gain Loss On Investment Securities
—
—
-0.53
-242.28%
0.37
Change In Working Capital
0.03
-99.19%
4.06
+681.66%
-0.70
-115.24%
4.58
Change In Receivables
—
—
0.33
-71.93%
1.16
Changes In Account Receivables
—
—
0.33
-71.93%
1.16
Change In Prepaid Assets
0.10
+121.81%
-0.46
-259.11%
0.29
+593.22%
-0.06
Change In Payables And Accrued Expense
-0.07
-101.50%
4.52
+557.33%
-0.99
-128.42%
3.48
Change In Accrued Expense
-0.29
-107.21%
4.01
+1222.41%
-0.36
-114.43%
2.47
Change In Payable
0.22
-57.17%
0.52
+181.65%
-0.63
-162.82%
1.01
Change In Account Payable
0.22
-57.17%
0.52
+181.65%
-0.63
-162.82%
1.01
Investing Cash Flow
-0.02
+98.84%
-2.08
-341.49%
-0.47
+35.79%
-0.73
Cash Flow From Continuing Investing Activities
-0.02
+98.84%
-2.08
-341.49%
-0.47
+35.79%
-0.73
Capital Expenditure
-0.02
+98.84%
-2.08
-341.49%
-0.47
+35.79%
-0.73
Capital Expenditure Reported
-0.02
+98.84%
-2.08
-341.49%
-0.47
+35.79%
-0.73
Financing Cash Flow
60.08
-55.72%
135.69
+99.16%
68.13
+55.59%
43.79
Cash Flow From Continuing Financing Activities
60.08
-55.72%
135.69
+99.16%
68.13
+55.59%
43.79
Net Issuance Payments Of Debt
9.47
0.00
0.00
-100.00%
9.82
Issuance Of Debt
19.69
0.00
0.00
-100.00%
9.82
Repayment Of Debt
-10.21
0.00
—
—
Long Term Debt Issuance
19.69
0.00
0.00
-100.00%
9.82
Long Term Debt Payments
-10.21
0.00
—
—
Net Long Term Debt Issuance
9.47
0.00
0.00
-100.00%
9.82
Net Common Stock Issuance
49.83
-63.78%
137.58
0.00
-100.00%
0.04
Common Stock Payments
-0.17
0.00
—
—
Repurchase Of Capital Stock
-0.17
0.00
—
—
Proceeds From Stock Option Exercised
0.70
+275.94%
0.19
+3.31%
0.18
—
Net Other Financing Charges
0.07
+103.23%
-2.08
-1.17%
-2.05
-501.47%
-0.34
Changes In Cash
8.29
-90.39%
86.19
+151.93%
34.21
+50.96%
22.66
Effect Of Exchange Rate Changes
-0.03
-172.73%
-0.01
-37.50%
-0.01
+66.67%
-0.02
Beginning Cash Position
168.73
+104.40%
82.55
+70.75%
48.34
+88.07%
25.70
End Cash Position
176.98
+4.89%
168.73
+104.40%
82.55
+70.75%
48.34
Free Cash Flow
-51.79
-4.63%
-49.50
-45.94%
-33.92
-60.55%
-21.13
Interest Paid Supplemental Data
1.66
+66.17%
1.00
+9.54%
0.91
0.00
Common Stock Issuance
50.00
-63.66%
137.58
0.00
-100.00%
0.04
Issuance Of Capital Stock
50.00
-63.66%
137.58
+96.54%
70.00
+104.05%
34.30
Net Preferred Stock Issuance
—
0.00
-100.00%
70.00
+104.31%
34.26
Preferred Stock Issuance
—
0.00
-100.00%
70.00
+104.31%
34.26
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category